Peptide Receptor Radiotherapy as a Potential Tool of Neoadjuvant Therapy in Patients with Inoperable Neuroendocrine Tumors (NETs)


Introduction: Neoadjuvant treatment is used as pre-surgical therapy in different cancers to decrease tumor size. PRRT can be a useful tool in neoadjuvant treatment of patients with well-differentiated NETs.

Aim(s): To assess using PRRT in primary inoperable NET and show neoadjuvant treatment results in downstaging of the tumor and option of surgery.

Materials and methods: Six patients - five foregut - four PNT, one midgut were included for PRRT every 6-9 weeks. Mean dose - 376 mCi. Tumor mean size was 96.2 mm. Only one patient had metastases to the liver. Cytoreduction chemotherapy was not used.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Sowa-Staszczak A, Pach D, Stefanska A, Tomaszuk M, Mikolajczak R,

Keywords: neoadjuvant therapy, PRRT, NET,

To read the full abstract, please log into your ENETS Member account.